Karen Wong1, Geoff P Delaney2, Michael B Barton3. 1. Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Ingham Institute for Applied Medical Research, Liverpool Hospital, UNSW Australia, Sydney, Australia; Department of Radiation Oncology, Cancer Therapy Centre, Liverpool Hospital, Sydney, Australia. Electronic address: karen.wong@sswahs.nsw.gov.au. 2. Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Ingham Institute for Applied Medical Research, Liverpool Hospital, UNSW Australia, Sydney, Australia; Department of Radiation Oncology, Cancer Therapy Centre, Liverpool Hospital, Sydney, Australia; University of Western Sydney, Australia. 3. Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Ingham Institute for Applied Medical Research, Liverpool Hospital, UNSW Australia, Sydney, Australia; Department of Radiation Oncology, Cancer Therapy Centre, Liverpool Hospital, Sydney, Australia.
Abstract
BACKGROUND AND PURPOSE: The recently updated optimal radiotherapy utilisation model estimated that 48.3% of all cancer patients should receive external beam radiotherapy at least once during their disease course. Adapting this model, we constructed an evidence-based model to estimate the optimal number of fractions for notifiable cancers in Australia to determine equipment and workload implications. MATERIALS AND METHODS: The optimal number of fractions was calculated based on the frequency of specific clinical conditions where radiotherapy is indicated and the evidence-based recommended number of fractions for each condition. Sensitivity analysis was performed to assess the impact of variables on the model. RESULTS: Of the 27 cancer sites, the optimal number of fractions for the first course of radiotherapy ranged from 0 to 23.3 per cancer patient, and 1.5 to 29.1 per treatment course. Brain, prostate and head and neck cancers had the highest average number of fractions per course. Overall, the optimal number of fractions was 9.4 per cancer patient (range 8.7-10.0) and 19.4 per course (range 18.0-20.7). CONCLUSIONS: These results provide valuable data for radiotherapy services planning and comparison with actual practice. The model can be easily adapted by inserting population-specific epidemiological data thus making it applicable to other jurisdictions.
BACKGROUND AND PURPOSE: The recently updated optimal radiotherapy utilisation model estimated that 48.3% of all cancerpatients should receive external beam radiotherapy at least once during their disease course. Adapting this model, we constructed an evidence-based model to estimate the optimal number of fractions for notifiable cancers in Australia to determine equipment and workload implications. MATERIALS AND METHODS: The optimal number of fractions was calculated based on the frequency of specific clinical conditions where radiotherapy is indicated and the evidence-based recommended number of fractions for each condition. Sensitivity analysis was performed to assess the impact of variables on the model. RESULTS: Of the 27 cancer sites, the optimal number of fractions for the first course of radiotherapy ranged from 0 to 23.3 per cancerpatient, and 1.5 to 29.1 per treatment course. Brain, prostate and head and neck cancers had the highest average number of fractions per course. Overall, the optimal number of fractions was 9.4 per cancerpatient (range 8.7-10.0) and 19.4 per course (range 18.0-20.7). CONCLUSIONS: These results provide valuable data for radiotherapy services planning and comparison with actual practice. The model can be easily adapted by inserting population-specific epidemiological data thus making it applicable to other jurisdictions.
Authors: Wei Liu; Alissa Liu; Jessica Chan; R Gabriel Boldt; Pablo Munoz-Schuffenegger; Alexander V Louie Journal: Transl Lung Cancer Res Date: 2019-09
Authors: Berend J Slotman; Mary Ann Clark; Enis Özyar; Myungsoo Kim; Jun Itami; Agnès Tallet; Jürgen Debus; Raphael Pfeffer; PierCarlo Gentile; Yukihiro Hama; Nicolaus Andratschke; Olivier Riou; Philip Camilleri; Claus Belka; Magali Quivrin; BoKyong Kim; Anders Pedersen; Mette van Overeem Felter; Young Il Kim; Jin Ho Kim; Martin Fuss; Vincenzo Valentini Journal: Radiat Oncol Date: 2022-08-22 Impact factor: 4.309